GLP-1 medications are reshaping how health systems think about insurance coverage. Jefferson Health, based in Philadelphia, is one of the most prominent systems grappling with this challenge — and it is responding with a structured, clinician-led approach that goes well beyond simply writing prescriptions.
GLP-1 Drugs and the Growing Insurance Burden
A Cost That Is Hard to Ignore
Jefferson Health and its insurer arm, Jefferson Health Plans, serve both plan members and approximately 65,000 employees. Together, these populations represent a large exposure to GLP-1 drug costs — costs that have risen sharply in recent years.
In a statement shared with Becker’s on April 17, Jefferson acknowledged that many insurers across the country have been forced to restrict or drop coverage of these medications. The reason is straightforward: pricing has become unsustainable. Jefferson added that it continues to advocate for more reasonable drug pricing models, so that evidence-based obesity care can expand more equitably across patient populations.
How Prescription Costs Are Reshaping Jefferson’s Budget
From 14% to 40% in a Decade
Jefferson CEO Joseph Cacchione, MD, spoke with NBC News about the financial strain GLP-1s have placed on the organization. His figures are striking. Last year, prescription drugs made up 40% of Jefferson’s total insurance spending. Just ten years ago, that share stood at only 14%.
Moreover, Dr. Cacchione attributed roughly one-third of the insurance division’s approximately $180 million operating loss in fiscal year 2025 to GLP-1 spending alone. That loss is significant, and it has forced Jefferson to rethink how it manages pharmaceutical costs across the board.
Today, Jefferson spends more on prescription drugs than it does on inpatient care — a shift that reflects the broader GLP-1 boom hitting health systems nationwide.
Jefferson’s Structured Weight Management Strategy
Diet and Lifestyle First, Then Medication
Rather than cutting GLP-1 access outright, Jefferson took a different path. The health system now requires employees under its self-funded plan to complete diet and lifestyle programs before they can access GLP-1 coverage. This prerequisite approach has produced measurable results — Dr. Cacchione told NBC News that it has saved Jefferson $20 million so far.
A Clinician-Centered Care Model
Jefferson’s official statement describes the program’s philosophy clearly. The system treats obesity as a chronic, complex condition that requires comprehensive, compassionate care — not a standalone prescription. Participants work directly with dedicated clinicians, who guide proper medication selection and dosing. They also receive ongoing support from dietitians to manage side effects and sustain long-term health improvements.
Furthermore, the program tracks engagement closely. Jefferson reported that more than 90% of participants remain actively enrolled in the employee weight management program — a strong adherence figure by any standard in chronic disease management.
Layoffs, Financial Pressures, and the Bigger Picture
GLP-1 Costs Are One Factor Among Many
Jefferson laid off more than 600 employees amid its financial difficulties. However, the health system was quick to clarify that GLP-1 spending was not the sole driver of that decision. In its statement, Jefferson noted that healthcare systems across the country are navigating pressure from multiple directions simultaneously — reimbursement challenges, rising labor costs, supply expenses, and increased pharmaceutical spending across many therapeutic categories.
GLP-1 costs are, as Jefferson put it, one component of a much broader financial picture. This distinction matters because it reflects a national pattern: health systems are under systemic pressure, and GLP-1s are simply the most visible pressure point right now.
What the Broader Industry Data Shows
Prescriptions Now Drive Premium Growth
The Jefferson situation does not exist in a vacuum. According to KFF research, roughly two-thirds of U.S. adults take at least one prescription medication. Additionally, a 2026 AHIP analysis found that more than 24 cents of every dollar in health insurance premiums now goes toward prescription drugs — making it the single largest spending category in coverage.
Premium Increases Loom for Employers
An October 2025 Employee Benefit Research Institute analysis projected that covering GLP-1 medications could raise employer-sponsored insurance premiums by 5% to 14%. Consequently, some employers are moving away from GLP-1 benefits altogether. For example, the Massachusetts state employee health plan announced it would drop GLP-1 coverage in response to costs.
These trends put organizations like Jefferson in a difficult position. They believe in the clinical value of GLP-1 medications. At the same time, they face real financial consequences from covering them at scale.
Key Takeaways for Health Systems and Payers
Jefferson Health’s experience offers several lessons for health systems and payers managing GLP-1 pressures. First, requiring lifestyle program participation before drug access can deliver meaningful savings without eliminating coverage entirely. Second, framing obesity treatment as a comprehensive care model — rather than a drug benefit — drives higher engagement and adherence. Third, financial stress from GLP-1s rarely exists in isolation; reimbursement gaps and labor costs usually compound it. Finally, transparency matters. Jefferson’s willingness to publicly discuss its losses, its layoffs, and its strategy sets a model for clear institutional communication during a period of industry-wide uncertainty.
